论文部分内容阅读
为探讨脐血输注的疗效机理，评价脐血输注的实用价值，我们用新鲜脐血静脉输注（ＵＣＢＴ），治疗慢性再生障碍性贫血（ＣＡＡ）１０例和急性白血病（ＡＬ）８例，观察ＵＣＢＴ前后患者粒单细胞系集落形成单位（ＣＦＵ－ＧＭ）、红系爆式集落形成单位（ＢＦＵ－Ｅ）、集落刺激活性（ＣＳＡ）、爆式集落刺激活性（ＢＰＡ）及外周血象变化。结果提示：ＵＣＢＴ后①可迅速升高ＣＦＵ－ＧＭ和ＢＦＵ－Ｅ；②可改善外周血象，尤其是ＷＢＣ、及ＡＮＣ和Ｈｂ；③可使病理性增高的ＣＳＡ、ＢＰＡ降至正常。结果提示可能系脐血中的祖细胞和造血因子刺激病人骨髓，并使造血功能得到改善。在某些病理情况下ＣＳＡ和ＢＰＡ的增高是机体的一种生物代偿反应，ＵＣＢＴ使病理增高的ＣＳＡ和ＢＰＡ显著下降并趋于正常可能是通过反馈调节作用而使细胞因子水平下降。
To explore the therapeutic mechanism of cord blood transfusion and evaluate the practical value of cord blood transfusion, we treated 10 cases of chronic aplastic anemia (CAA) and 8 cases of acute leukemia (AL) with fresh cord blood infusion (UCBT) (CFU-GM), erythrocytic burst forming units (BFU-E), colony stimulating activity (CSA), blast colony stimulating activity (BPA) and peripheral blood changes were observed before and after UCBT . The results suggest that: after UCBT ① can rapidly increase CFU-GM and BFU-E; ② can improve peripheral blood, especially WBC, and ANC and Hb; ③ pathological increased CSA, BPA normalized. The results suggest that cord blood progenitor cells and hematopoietic factors stimulate the patient’s bone marrow, and to improve hematopoietic function. Under some pathological conditions, the increase of CSA and BPA is a biocompatibility of the body. The decreased and normalized levels of CSA and BPA in UCBT may be caused by the feedback regulation of cytokine levels.